Clinical Trials

    Fulvestrant Plus Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

    Investigator: Polly Niravath

    Study Coordinator: Alexys Brock

    Status: Enrolling

    ClinicalTrials.gov Number: NCT05305924

    Phone: 346.238.4814

    Protocol Number: PRO00028925

    Description


    The study will investigate if a one month drug holiday from the CDK4/6 inhibitor drug, abemaciclib, will restore the body's sensitivity to the drug and make the subsequent treatment of abemaciclib plus fulvestrant more effective.